| Before | Following-up | P value | |
| Demographics |
|
|
|
| Body mass index (kg/m2) | 28.2 ± 7.1 | 27.5 ± 6.4 | 0.767 |
| Disease status |
|
|
|
| Physician’ VAS (0 - 10) | 0.0 (0.0 - 0.0) | 0.0 (0.0 - 0.0) | 0.552 |
| Patient’s VAS (0 - 10) | 5.0 (2.5 - 7.0) | 5.0 (2.0 - 7.0) | 0.777 |
| HAQ (0.00 - 3.00) | 0.5 (0.0 - 1.3) | 0.2 (0.0 - 1.0) | 0.325 |
| MMT-8 (0 - 80) | 80 (80 - 80) | 80 (80 - 80) | 0.155 |
| Creatine phosphokinase (U/L) | 112 (68 - 216) | 118 (68 - 214) | 0.876 |
| Treatment |
|
|
|
| Prednisone (%) | 11 (25.6) | 12 (27.9) | 0.808 |
| Prednisone (mg/day) | 0.0 (0.0 - 2.5) | 0.0 (0.0 - 2.0) | >0.999 |
| Methotrexate (%) | 5 (11.6) | 10 (23.3) | 0.155 |
| Azathioprine (%) | 6 (14.0) | 10 (23.3) | 0.268 |
| Mycophenolate mofetil (%) | 13 (30.2) | 12 (27.9) | 0.812 |
| Comorbidities |
|
|
|
| Depression (%) | 0 | 2 (4.7) | - |
| Fibromyalgia (%) | 4 (9.3) | 5 (11.6) | 0.725 |
| Pain perception (VAS) |
|
|
|
| Mild (0.0 - 3.0) | 15 (34.9) | 16 (37.2) |
|
| Moderate (4.0 - 8.0) | 16 (37.2) | 16 (37.2) | 0.963 |
| Intense (8.0 - 10) | 12 (27.9) | 11 (25.6) |
|
| Fatigue perception (VAS) |
|
|
|
| Mild (0.0 - 3.0) | 13 (30.2) | 12 (27.9) |
|
| Moderate (4.0 - 8.0) | 15 (34.9) | 17 (39.5) | 0.905 |
| Intense (8.0 - 10) | 15 (34.9) | 14 (32.6) |
|
| Fatigue severity |
|
|
|
| FSS (0.0 - 7.0) | 4.1 ± 1.9 | 4.5 ± 1.8 | 0.088 |
| Physical activity levels |
|
|
|
| Low | 31 (72.1) | 33 (76.7) |
|
| Moderate | 9 (20.9) | 6 (14.0) | 0.669 |
| High | 3 (7.0) | 4 (9.3) |
|